$RVNC
Revance Therapeutics, Inc. Stock $rvnc

$rvnc Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-Q Financial Statement

#000162828015004193 Filed on May 14, 2015

Income Statement

Concept	2015 Q1	2014 Q1
Revenue	$75.00K	$158.0K
YoY Change	-52.53%	110.67%
Cost Of Revenue		$0.00
YoY Change
Gross Profit		$158.0K
YoY Change		110.67%
Gross Profit Margin		100.0%
Selling, General & Admin	$5.996M	$4.093M
YoY Change	46.49%	83.96%
% of Gross Profit		2590.51%
Research & Development	$9.254M	$7.551M
YoY Change	22.55%	0.32%
% of Gross Profit		4779.11%
Depreciation & Amortization	$531.0K	$488.0K
YoY Change	8.81%	7.73%
% of Gross Profit		308.86%
Operating Expenses	$15.25M	$11.64M
YoY Change	30.97%	19.4%
Operating Profit	-$15.18M	-$11.49M
YoY Change	32.12%	18.69%
Interest Expense	$165.0K	$9.841M
YoY Change	-98.32%	-22.05%
% of Operating Profit
Other Income/Expense, Net	-$47.00K	$0.00
YoY Change		-100.0%
Pretax Income	-$15.40M	-$21.43M
YoY Change	-28.12%	-1.07%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$15.40M	-$21.43M
YoY Change	-28.12%	-1.07%
Net Earnings / Revenue	-20536.0%	-13560.76%
Basic Earnings Per Share	-$0.65	-$1.93
Diluted Earnings Per Share	-$0.65	-$1.93
COMMON SHARES
Basic Shares Outstanding	23.54M shares	11.09M shares
Diluted Shares Outstanding	23.54M shares	11.09M shares

Balance Sheet

Concept	2015 Q1	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$153.7M	$87.90M
YoY Change	74.86%	226.77%
Cash & Equivalents	$153.7M	$87.85M
Short-Term Investments
Other Short-Term Assets	$1.900M	$26.00K
YoY Change	7207.69%	-98.14%
Inventory
Prepaid Expenses		$1.082M
Receivables		$1.786M
Other Receivables		$0.00
Total Short-Term Assets	$155.7M	$91.17M
YoY Change	70.76%	223.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$19.39M	$15.15M
YoY Change	27.99%	119.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$243.0K	$155.0K
YoY Change	56.77%	-88.08%
Total Long-Term Assets	$20.03M	$15.74M
YoY Change	27.27%	91.95%
TOTAL ASSETS
Total Short-Term Assets	$155.7M	$91.17M
Total Long-Term Assets	$20.03M	$15.74M
Total Assets	$175.7M	$106.9M
YoY Change	64.36%	193.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.089M	$3.689M
YoY Change	-43.37%	-0.3%
Accrued Expenses	$4.019M	$5.515M
YoY Change	-27.13%	-8.08%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$300.0K	$13.40M
YoY Change	-97.76%	59.52%
Total Short-Term Liabilities	$6.427M	$22.61M
YoY Change	-71.57%	-30.65%
LONG-TERM LIABILITIES
Long-Term Debt	$500.0K	$400.0K
YoY Change	25.0%	-96.19%
Other Long-Term Liabilities	$5.300M	$5.200M
YoY Change	1.92%	-5.45%
Total Long-Term Liabilities	$5.800M	$5.600M
YoY Change	3.57%	-65.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.427M	$22.61M
Total Long-Term Liabilities	$5.800M	$5.600M
Total Liabilities	$12.26M	$28.23M
YoY Change	-56.55%	-41.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$274.2M	-$217.3M
YoY Change	26.18%
Common Stock	$437.7M	$296.0M
YoY Change	47.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$163.5M	$78.69M
YoY Change
Total Liabilities & Shareholders Equity	$175.7M	$106.9M
YoY Change	64.36%	193.71%

Cashflow Statement

Concept	2015 Q1	2014 Q1
OPERATING ACTIVITIES
Net Income	-$15.40M	-$21.43M
YoY Change	-28.12%	-1.07%
Depreciation, Depletion And Amortization	$531.0K	$488.0K
YoY Change	8.81%	7.73%
Cash From Operating Activities	-$13.03M	-$21.11M
YoY Change	-38.28%	220.76%
INVESTING ACTIVITIES
Capital Expenditures	$1.801M	$985.0K
YoY Change	82.84%	203.08%
Acquisitions
YoY Change
Other Investing Activities	$80.00K	$80.00K
YoY Change	0.0%	0.0%
Cash From Investing Activities	-$1.726M	-$910.0K
YoY Change	89.67%	264.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$102.7M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$2.563M	$106.0M
YoY Change	-102.42%	257.23%
NET CHANGE
Cash From Operating Activities	-$13.03M	-$21.11M
Cash From Investing Activities	-$1.726M	-$910.0K
Cash From Financing Activities	-$2.563M	$106.0M
Net Change In Cash	-$17.32M	$83.94M
YoY Change	-120.63%	267.67%
FREE CASH FLOW
Cash From Operating Activities	-$13.03M	-$21.11M
Capital Expenditures	$1.801M	$985.0K
Free Cash Flow	-$14.83M	-$22.09M
YoY Change	-32.88%	219.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q1	dei	Amendment Flag AmendmentFlag	false
CY2015Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2015Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015Q1	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
CY2015Q1	dei	Document Type DocumentType	10-Q
CY2015Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001479290
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23946650	shares
CY2015Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2015Q1	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	1999-08-10
CY2015Q1	dei	Entity Information Date To Change Former Legal Or Registered Name EntityInformationDateToChangeFormerLegalOrRegisteredName	2005-04-19
CY2015Q1	dei	Entity Registrant Name EntityRegistrantName	Revance Therapeutics, Inc.
CY2015Q1	rvnc	Cashand Cash Equivalents Operating Plan Funding Term CashandCashEquivalentsOperatingPlanFundingTerm	P12M
CY2014Q1	rvnc	Changein Fair Valueof Convertible Preferred Stock Warrant ChangeinFairValueofConvertiblePreferredStockWarrant	-210000	USD
CY2015Q1	rvnc	Changein Fair Valueof Convertible Preferred Stock Warrant ChangeinFairValueofConvertiblePreferredStockWarrant	0	USD
CY2014Q1	rvnc	Conversion Of Preferred Stock Warrants To Common Stock Warrants ConversionOfPreferredStockWarrantsToCommonStockWarrants	1441000	USD
CY2015Q1	rvnc	Conversion Of Preferred Stock Warrants To Common Stock Warrants ConversionOfPreferredStockWarrantsToCommonStockWarrants	0	USD
CY2014Q1	rvnc	Extinguishmentof Warrant Liability Upon Exerciseof Put Option ExtinguishmentofWarrantLiabilityUponExerciseofPutOption	1356000	USD
CY2015Q1	rvnc	Extinguishmentof Warrant Liability Upon Exerciseof Put Option ExtinguishmentofWarrantLiabilityUponExerciseofPutOption	0	USD
CY2014Q4	rvnc	Financing Lease Obligation Noncurrent Netof Current Portion FinancingLeaseObligationNoncurrentNetofCurrentPortion	598000	USD
CY2015Q1	rvnc	Financing Lease Obligation Noncurrent Netof Current Portion FinancingLeaseObligationNoncurrentNetofCurrentPortion	513000	USD
CY2014Q4	rvnc	Financing Obligation Current FinancingObligationCurrent	307000	USD
CY2015Q1	rvnc	Financing Obligation Current FinancingObligationCurrent	319000	USD
CY2015Q1	rvnc	Financing Obligation Future Minimum Payments Due FinancingObligationFutureMinimumPaymentsDue	881000	USD
CY2015Q1	rvnc	Financing Obligation Future Minimum Payments Duein Three Years FinancingObligationFutureMinimumPaymentsDueinThreeYears	141000	USD
CY2015Q1	rvnc	Financing Obligation Future Minimum Payments Duein Two Years FinancingObligationFutureMinimumPaymentsDueinTwoYears	423000	USD
CY2015Q1	rvnc	Financing Obligation Future Minimum Payments Next Twelve Months FinancingObligationFutureMinimumPaymentsNextTwelveMonths	317000	USD
CY2014Q1	rvnc	Gain Loss On Settlement In Exchange Of Preferred Stock Warrants GainLossOnSettlementInExchangeOfPreferredStockWarrants	-1356000	USD
CY2015Q1	rvnc	Gain Loss On Settlement In Exchange Of Preferred Stock Warrants GainLossOnSettlementInExchangeOfPreferredStockWarrants	0	USD
CY2014Q1	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-416000	USD
CY2015Q1	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-42000	USD
CY2014Q1	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	231000	USD
CY2015Q1	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	0	USD
CY2014Q1	rvnc	Interest Expense Convertible Notes InterestExpenseConvertibleNotes	1250000	USD
CY2015Q1	rvnc	Interest Expense Convertible Notes InterestExpenseConvertibleNotes	0	USD
CY2014Q1	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	52000	USD
CY2015Q1	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	39000	USD
CY2014Q1	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	67000	USD
CY2015Q1	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	5000	USD
CY2014Q1	rvnc	Issuance Of Common Stock Upon Net Exercise Of Warrants IssuanceOfCommonStockUponNetExerciseOfWarrants	6490000	USD
CY2015Q1	rvnc	Issuance Of Common Stock Upon Net Exercise Of Warrants IssuanceOfCommonStockUponNetExerciseOfWarrants	0	USD
CY2014Q1	rvnc	Issuance Of Common Stock Warrants IssuanceOfCommonStockWarrants	981000	USD
CY2015Q1	rvnc	Issuance Of Common Stock Warrants IssuanceOfCommonStockWarrants	0	USD
CY2014Q1	rvnc	Issuance Of Convertible Preferred Stock Warrants IssuanceOfConvertiblePreferredStockWarrants	80000	USD
CY2015Q1	rvnc	Issuance Of Convertible Preferred Stock Warrants IssuanceOfConvertiblePreferredStockWarrants	0	USD
CY2014Q1	rvnc	Modification Of Preferred Stock In Accordance With Settlement Agreement ModificationOfPreferredStockInAccordanceWithSettlementAgreement	17000	USD
CY2015Q1	rvnc	Modification Of Preferred Stock In Accordance With Settlement Agreement ModificationOfPreferredStockInAccordanceWithSettlementAgreement	0	USD
CY2014Q1	rvnc	Noncash Deferred Initial Public Offering Costs NoncashDeferredInitialPublicOfferingCosts	4028000	USD
CY2015Q1	rvnc	Noncash Deferred Initial Public Offering Costs NoncashDeferredInitialPublicOfferingCosts	0	USD
CY2014Q1	rvnc	Noncash Interest Expense NoncashInterestExpense	9469000	USD
CY2015Q1	rvnc	Noncash Interest Expense NoncashInterestExpense	55000	USD
CY2014Q1	rvnc	Revaluation Of Convertible Redeemable Preferred Stock Warrants RevaluationOfConvertibleRedeemablePreferredStockWarrants	210000	USD
CY2015Q1	rvnc	Revaluation Of Convertible Redeemable Preferred Stock Warrants RevaluationOfConvertibleRedeemablePreferredStockWarrants	0	USD
CY2014Q1	rvnc	Terminationof Stock Option Repurchase Right Noncash TerminationofStockOptionRepurchaseRightNoncash	58000	USD
CY2015Q1	rvnc	Terminationof Stock Option Repurchase Right Noncash TerminationofStockOptionRepurchaseRightNoncash	0	USD
CY2015Q1	rvnc	Working Capital Surplus WorkingCapitalSurplus	149300000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3149000	USD
CY2015Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2089000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4145000	USD
CY2015Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4019000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	435142000	USD
CY2015Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	437633000	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	810000	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2317000	USD
CY2014Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1046000	USD
CY2015Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	5000	USD
CY2014Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	52000	USD
CY2015Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	39000	USD
CY2014Q4	us-gaap	Assets Assets	192469000	USD
CY2015Q1	us-gaap	Assets Assets	175722000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	172731000	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	155689000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3914000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	87853000	USD
CY2014Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	4032000	USD
CY2015Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	171032000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	153717000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	83939000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-17315000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23774465	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23944861	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23774465	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23944861	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2014Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	123982000	USD
CY2015Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2014Q1	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	26206000	USD
CY2015Q1	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3725000	USD
CY2015Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3741000	USD
CY2014Q1	us-gaap	Depreciation Depreciation	488000	USD
CY2015Q1	us-gaap	Depreciation Depreciation	531000	USD
CY2014Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1541000	USD
CY2015Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1583000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.93
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.93
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2014Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2151000	USD
CY2015Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	166038000	USD
CY2015Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	148562000	USD
CY2014Q1	us-gaap	Financing Interest Expense FinancingInterestExpense	0	USD
CY2015Q1	us-gaap	Financing Interest Expense FinancingInterestExpense	11000	USD
CY2014Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-8331000	USD
CY2015Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1944000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1195000	USD
CY2014Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1813000	USD
CY2015Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1175000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-83000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2014Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-7073000	USD
CY2015Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	USD
CY2014Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1253000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	213000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2428000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	352000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-403000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-16000	USD
CY2014Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-75000	USD
CY2015Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-75000	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	9841000	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	165000	USD
CY2014Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	271000	USD
CY2015Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2014Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	372000	USD
CY2015Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	110000	USD
CY2014Q1	us-gaap	Interest Paid InterestPaid	372000	USD
CY2015Q1	us-gaap	Interest Paid InterestPaid	110000	USD
CY2014Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	2000	USD
CY2015Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	27000	USD
CY2014Q1	us-gaap	Lessee Leasing Arrangements Operating Leases Renewal Term LesseeLeasingArrangementsOperatingLeasesRenewalTerm	P36M
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21106000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13026000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-21426000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-15402000	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21426000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15402000	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-21426000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-15402000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	16100000	USD
CY2015Q1	us-gaap	Liabilities Liabilities	12264000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	192469000	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	175722000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10236000	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6427000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	105955000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2563000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-910000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1726000	USD
CY2014Q1	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	3594000	USD
CY2015Q1	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	194000	USD
CY2014Q1	us-gaap	Notes Assumed1 NotesAssumed1	1050000	USD
CY2015Q1	us-gaap	Notes Assumed1 NotesAssumed1	0	USD
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2635000	USD
CY2015Q1	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	11644000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	15250000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11486000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15175000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	52355000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	3807000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	5578000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	5394000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	5222000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	32354000	USD
CY2014Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1300000	USD
CY2015Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1300000	USD
CY2015Q1	us-gaap	Operations Commenced Date1 OperationsCommencedDate1	2002-06-30
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	29000	USD
CY2015Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	243000	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-47000	USD
CY2014Q1	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	1438000	USD
CY2015Q1	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	985000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1801000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1624000	USD
CY2015Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1937000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	102672000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2014Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	6750000	USD
CY2015Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15000	USD
CY2015Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	173000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19274000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19390000	USD
CY2015Q1	us-gaap	Purchase Obligation PurchaseObligation	21700000	USD
CY2014Q1	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	2000	USD
CY2015Q1	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	84000	USD
CY2014Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2042000	USD
CY2015Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2652000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7551000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9254000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	75000	USD
CY2015Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	35000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	435000	USD
CY2015Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	400000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-258797000	USD
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-274199000	USD
CY2014Q1	us-gaap	Revenues Revenues	158000	USD
CY2015Q1	us-gaap	Revenues Revenues	75000	USD
CY2014Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4093000	USD
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5996000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	810000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2317000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	176369000	USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	163458000	USD
CY2014Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11092471	shares
CY2015Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23535080	shares
CY2014Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11092471	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23535080	shares
CY2015Q1	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicis Settlement</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">October 2012</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a settlement and termination agreement with Medicis Pharmaceutical Corporation, or Medicis. Medicis was subsequently acquired by Valeant Pharmaceuticals International, Inc. in December 2012. The terms of the settlement provided for the reacquisition of the rights related to all territories of RT001 and RT002 from Medicis and for consideration payable by the Company to Medicis of up to </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;">, comprised of (i) an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">, which was paid in 2012, (ii) a Proceeds Sharing Arrangement Payment of </font><font style="font-family:inherit;font-size:10pt;">$14.0 million</font><font style="font-family:inherit;font-size:10pt;"> due upon specified capital raising achievements by the Company, of which </font><font style="font-family:inherit;font-size:10pt;">$6.9 million</font><font style="font-family:inherit;font-size:10pt;"> was paid in 2013 and the remaining </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;"> was paid in 2014, and (iii) </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> to be paid upon the achievement of specified regulatory milestones by the Company, or Product Approval Payment. </font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company determined the fair value of its liability for the Product Approval Payment was </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">, which was measured by assuming a term of </font><font style="font-family:inherit;font-size:10pt;">3.25</font><font style="font-family:inherit;font-size:10pt;"> years, a risk-free rate of </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </font><font style="font-family:inherit;font-size:10pt;">6.5%</font><font style="font-family:inherit;font-size:10pt;">. The Company’s assumption for the expected term is based on an expected Biologics License Application, or BLA, approval in 2018. The Company did not make any payments under the Product Approval Payment during the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>
CY2015Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include the fair value of common stock, stock-based compensation, fair value of convertible preferred stock and warrants, fair value of derivatives, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and also on assumptions that it believes are reasonable, however, actual results could significantly differ from those estimates</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-15-004193-index-headers.html	Edgar Link	pending
0001628280-15-004193-index.html	Edgar Link	pending
0001628280-15-004193.txt	Edgar Link	pending
0001628280-15-004193-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rvnc-20150331.xml	Edgar Link	completed
rvnc-20150331.xsd	Edgar Link	pending
rvnc-20150331_cal.xml	Edgar Link	unprocessable
rvnc-20150331_def.xml	Edgar Link	unprocessable
rvnc-20150331_lab.xml	Edgar Link	unprocessable
rvnc-20150331_pre.xml	Edgar Link	unprocessable
rvnc03311510q.htm	Edgar Link	pending
rvnc331201510qex102.htm	Edgar Link	pending
rvnc331201510qex104.htm	Edgar Link	pending
rvnc331201510qex311.htm	Edgar Link	pending
rvnc331201510qex312.htm	Edgar Link	pending
rvnc331201510qex321.htm	Edgar Link	pending
rvnc331201510qex322.htm	Edgar Link	pending
rvncgraphic01.jpg	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RVNC
Revance Therapeutics, Inc. Stock $rvnc

2015 Q1 Form 10-Q Financial Statement

#000162828015004193 Filed on May 14, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC Revance Therapeutics, Inc. Stock $rvnc

2015 Q1 Form 10-Q Financial Statement

#000162828015004193 Filed on May 14, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC
Revance Therapeutics, Inc. Stock $rvnc